Here we employ a set of RNA Polymerase II (Pol II) activity mutants to determine the consequences of 13 increased or decreased Pol II catalysis on gene expression in Saccharomyces cerevisiae. We find that 14 alteration of Pol II catalytic rate, either fast or slow, leads to decreased Pol II occupancy and apparent 15 reduction in elongation rate in vivo. However, we also find that determination of elongation rate in vivo by 16 chromatin IP can be confounded by the kinetics and conditions of transcriptional shutoff in the assay. We 17 identify promoter and template-specific effects on severity of gene expression defects for both fast and 18 slow Pol II mutants. We show that mRNA half-lives for a reporter gene are increased in both fast and 19
Introduction 26
Gene transcription by RNA polymerase II (Pol II) is an essential process and involves three distinct 27 phases: initiation, elongation and termination. Transcription elongation proceeds through an iterative 28 cycle of substrate selection, catalysis of phosphodiester bond formation, and enzyme translocation 29 [Reviewed in (1, 2) ]. Pausing, backtracking, and arrest of Pol II can occur during elongation. Pol II 30 elongation factors are proposed to promote Pol II elongation by modulating these processes or 31 otherwise enabling Pol II to overcome obstacles. Coordinated with elongating Pol II, several co-32
transcriptional events occur to control the fate of nascent RNAs and ensure proper gene expression 33 [Reviewed in (3) ]. Thus, it is likely that perturbation of Pol II elongation will have multi-faceted effects in 34 vivo. To understand the complexity of Pol II activity-mediated control of gene expression it is necessary 35
to understand how alteration of Pol II catalytic activity relates to specific gene expression defects. 36
Studies from our lab and others have identified several Pol II catalytic mutants that can alter elongation 37 rate in vitro (4-6). Based on these mutants' ability to increase or decrease transcription elongation rate 38 relative to wild type (WT), we term them "gain of function" (GOF) or "loss of function" (LOF) mutants, 39 respectively (4). These classes of mutant confer distinct gene expression profiles, genetic interaction 40 profiles, splicing, and transcription initiation defects in vivo, consistent with their having distinct 41 biochemical defects in vitro (4, 7, 8) . Most of these mutants reside in a highly conserved, mobile sub-42 domain of the largest Pol II subunit Rpb1, known as the trigger loop (TL) (4) (5) (6) 9) . The TL is a component 43 of the Pol II catalytic center, and can directly interact with incoming NTPs, undergoing conformational 44 changes to promote rapid catalysis (5, 10, 11) . TL mutants have been shown to affect a number of Pol II 45 biochemical properties including catalysis, substrate selection and transcription fidelity (5, 11) . In 46 addition, TL mutants have been also shown to affect Pol II translocation, pausing and intrinsic cleavage 47
properties (12) (13) (14) . 48
The rate of transcription elongation has likely evolved to facilitate and enhance the efficiency of pre-49 mRNA processing and maturation [Reviewed in (3) ]. Maturation of pre-mRNA requires addition of a 7-50 methyl guanosine cap at the 5'-end of the transcript, splicing of introns, and addition of a poly(A) tail to 51 the 3'-end of the transcript. Further, the pre-mRNA is uniquely packaged with protein components into a 52 mature mRNA granule, which facilitates export and efficient translation. Impaired processing leads to 53 degradation of pre-mRNAs by nuclear surveillance pathways. Mechanistic coupling of transcription and 54 pre-mRNA processing is achieved through recruitment of factors by C-terminal domain (CTD) and by 55 kinetic competition between transcription and processing [Reviewed in (3) ]. Using Pol II catalytic 56 mutants, it has been shown that kinetic competition functions in the efficiency of pre-mRNA splicing 57 (7, (15) (16) (17) . At least one Pol II catalytic mutant has been reported to be defective in 5'-capping, leading to 58 the degradation of transcript by 5' to 3' nuclear exonuclease (18) . Additionally, a number of findings 59 suggest kinetic competition between transcription termination and elongation in both yeast and human 60 cells (19, 20) . Recently, a competition-independent pathway has been proposed for termination that 61 occurs through a conformational change to Pol II (21). Furthermore, it has been proposed that overall 62
RNA synthesis rate is connected to mRNA decay rate through feedback between synthesis and 63 degradation (22) (23) (24) (25) (26) . Growth rate is also proposed to control mRNA decay and overall mRNA 64 abundance, but linkages between RNA synthesis rate, growth, and mRNA decay have not been 65 determined at the molecular level (27,28)(http://biorxiv.org/content/early/2016/03/19/044735). 66
In order to study Pol II elongation in vivo, a number of methods have been implemented that either 67 directly measure apparent Pol II elongation rate or determine indirect consequences of elongation rate 68 (29-32) (for a of list methods and estimated in vivo Pol II elongation rates see here (33)). Two methods 69
are generally used to study elongation in yeast, one to study elongation properties and the other to 70 genetically implicate factors in elongation control. The first utilizes chromatin immunoprecipitation (ChIP) 71
to determine Pol II occupancy across a long galactose-inducible gene, GAL1p::YLR454w, either in 72 steady state or after transcription shutoff by addition of glucose (29) . Apparent processivity is inferred 73 from comparison of steady state Pol II occupancy for wild type and transcription mutants, while kinetics 74 of the 'last wave' of Pol II leaving the template can be used to determine the apparent elongation rate. 75 Indeed, Pol II catalytic mutants and several mutant factors have shown altered apparent in vivo 76 elongation rate and apparent processivity defects in this assay ( Supplementary Table 1 ). Interpretation 77 of apparent elongation rate differences based on transcriptional shutoff makes assumptions that 78 signaling and kinetics of the shutoff are identical between WT and mutant strains. Similarly, in a second 79 widely used approach, genetic detection of elongation defects through use of nucleotide-depleting drugs 80 makes assumptions that drug effects are identical between WT and mutant strains, and this issue is 81 discussed below. 82
Nucleotide-depleting drugs, such as mycophenolic acid (MPA), which limits cellular GTP levels by 83
inhibiting IMPDH activity, are assumed to elicit transcription elongation defects by enhancing pausing, 84
arrest, or backtracking due to limitation in substrate levels (1, (34) (35) (36) (37) . Growth sensitivity to MPA for Pol II 85 or presumptive elongation factor mutants has been widely interpreted as a synergistic effect between 86
MPA treatment and impaired elongation due to the mutant. The notion that limiting nucleotide is the 87 major determinant of drug phenotypes was further strengthened by the observation that guanine 88 supplementation suppresses sensitivity to the drug, along with the observation of elongation defects due 89 to drug treatment (29, 38 Here, we present a detailed molecular analysis of how alteration to Pol II catalysis rate through the use 102 of specific rpb1 alleles, conferring slower or faster catalysis than wild type in vitro, affects several facets 103 of transcription and gene expression in vivo (a summary of observed mutant effects is in 104
Supplementary Table 2 ). Using the widely used GAL1p::YLR454w reporter, we show that both slow 105 and fast Pol II catalytic mutants decrease Pol II occupancy and reporter gene expression in vivo. We find 106 that the reporter gene expression defects in slow or fast Pol II mutants negatively correlate with 107 increased reporter mRNA half-lives. Pol II catalytic mutants show genetic interaction with pre-mRNA 108
processing factors, and we present evidence for an mRNA processing defect in fast catalytic mutants. 109
Finally, we have critically evaluated the two major widely used systems for studying transcription 110 elongation in yeast -chromatin IP of the 'last wave' of Pol II upon transcription inhibition, and response 111 to GTP starvation. For both assays we uncover underlying biological complexities that differentially affect 112
WT and presumptive elongation mutant cells, confounding interpretation of these assays by simple 113 models. Our results provide a useful framework for future utilization of Pol II catalytic mutants to probe 114 biological processes and gene expression mechanisms. 115
MATERIAL AND METHODS 116
Yeast strains, plasmid, media and growth 117 Yeast strains and plasmids used in this study are listed in Supplementary Table 3 Aldrich). Minimal media plates were prepared with synthetic complete (SC) or 'Hopkins mix' with 125 appropriate amino acid(s) dropped out as described in (43), with slight modifications as described in (4). 126
For studies with mycophenolic acid (MPA, Sigma-Aldrich), a stock solution (10 mg/ml, in 100% ethanol) 127
of MPA was added to solid or liquid media to achieve desired concentration. NaOH, HCl and Guanine 128
were added to solid media to achieve desired concentration as indicated. Liquid YPD, YPRaf, YPGal 129
and YPRafGal media are prepared with yeast extract (1% w/v), peptone (2% w/v) and 2% (w/v) carbon 130 source (dextrose, raffinose, galactose or raffinose plus galactose), with no supplementary adenine, 131 tryptophan or Antimycin A. Antimycin A is a standard additive to yeast plates when growth on 132 fermentable carbon sources such as galactose or raffinose is being assayed. Prevention of respiration 133 enforces growth by fermentation. These assays can be performed in the absence of Antimycin A (which 134 is a highly toxic substance), but they become less sensitive as the growth differenced between WT 135 gal10∆56 strains on YPRafGal and mutants that suppress galactose toxicity on YPRafGal are lessened. 136
Yeast phenotyping assays were performed by serial dilution and spotting onto plates as described earlier 137
(4). Doubling times for the mutants in liquid medium (YPGal) were determined using Tecan plate-reader 138 as described earlier (44) biological replicate and was analyzed in Graphpad Prism using an exponential-growth fitting function. 142
Chromatin immunoprecipitation 143
All the strains used for ChIP experiments contained a C-terminal epitope tag on the Rpb3 subunit of 144 RNA Pol II (RPB3::3XFLAG::KANMX; see strain list). ChIP experiments were performed as described 145 previously (45). Briefly, 100 ml of mid-log phase cells (~1x10 7 cells/ml) were cross-linked with 1% 146 formaldehyde (final) for 20 min, and then quenched with 15 ml of 2.5 M glycine for 5 min. Cross-linked 147 cells were washed twice with cold 1X TBS buffer at 3500 rpm for 3-4 min at 4˚C using a JS-5.3 rotor 148
(Avanti J-26 XP centrifuge, Beckman-Coulter) and were disrupted by bead beating with glass beads in 149 lysis buffer (0.1 M Tris pH 8.0, glycerol 20%, 1 mM PMSF). Cross-linked cell lysates were subjected to a 150 low speed spin (1500 rpm, 1 min at 4˚C) to remove cell-debris, followed by centrifugation of chromatin 151 pellets, subsequent washing of pellets (twice) with 1 ml FA buffer (50 mM HEPES-KOH pH 7.5, 300 mM 152 NaCl, 1 mM EDTA, 0.1% Triton X-100, 0.01% sodium deoxycholate, 0.1% SDS and 1 mM PMSF) at 153 14000 rpm for 20 min at 4˚C using F45-30-11 rotor (Centrifuge 5417R, Eppendorf For in vivo elongation assays, WT or mutant cells were grown in YPGal to mid-log phase and a pre-176 glucose shutoff sample was taken for the 0 minute time point. Then glucose (4% final) was added to 177 inhibit transcription and aliquots were removed after 2, 4, 6 and 8 minutes (optional longer time points 178
were taken for some strains). Alternatively, after isolation of 0 min sample as above, remainder of culture 179 was centrifuged and washed with SC medium lacking carbon source as described earlier (19), then 180 inoculated in YPD (4% glucose) media or SC media lacking carbon source to isolate glucose shutoff 181 samples or galactose-depletion samples, respectively, at indicated time points. Formaldehyde cross-182 linking, chromatin preparation and subsequent steps were performed as described above. 183
RNA isolation, Northern blotting 184
For gene expression analysis, RNAs were isolated from mid-log phase cells grown in appropriate 185 medium as described in the main text. Post shutoff samples were collected by a quick centrifugation for 186 1 min and immediate freezing of the cell pellets by placing at -80C. Centrifugation time was included 187 while calculating shutoff time. Total RNA was purified using hot phenol-chloroform method as described 188
previously (47). 189
Northern blotting was performed essentially as described in the manual for GeneScreen hybridization 190 membranes (Perkin-Elmer) with minor modifications as described earlier (4 Healthcare) and quantified using Quantity One (Bio-Rad). 200
Northern blotting for mapping the termination window of the pre-processed snR33 transcript was 201 performed essentially as described in (19,48) with minor modifications. Briefly, 5-8 µg of RNA were 202 separated on 6% polyacrylamide-7M urea gel. RNAs were transferred from polyacrylamide gel to a 203 membrane (GeneScreen Plus, PerkinElmer) with a Bio-Rad Trans-Blot apparatus at a setting of 45W for 204 1.5 hrs. RNAs were cross-linked to the membrane by UV light. Pre-hybridization of the membrane, probe 205 synthesis and membranes-hybridization were performed as described in (48). Membranes were washed 206 twice with low stringency wash buffer (0.1x SSC, 0.1% SDS) and visualized by phosphorimaging Rad or GE Healthcare). Lane traces were determined for each sample using ImageQuant (GE 208 Healthcare). 209
Primer extension 210
For primer extension (PE) analysis, RNA was isolated from mid-log phase cells grown in appropriate 211 media, optionally treated with desired concentration of MPA for indicated time periods. Primer extension 212 analysis was done essentially as described earlier (49) IMD2 TSS annotation we have considered 'A' of the start codon (ATG) as +1, so that bases upstream 219 start at -1, as in our previous publication (4). 220 221
Mig1p-GFP tagged strain was made by integrating GFP C-terminal tag at the genomic locus (see strain 223 description). Microscopy was performed as described previously (50), with modifications. Briefly, cells 224 grown overnight in SC medium (2% galactose) at 30˚C, diluted in fresh SC media and grown till mid-log 225 at 30˚C before microscopy. Perfusion chamber gasket (ThermoFisher, 4 chamber: 19 mm X 6 mm) was 226 used for changing medium. Chamber was treated with Con A (2 mg/ml, MP Biomedicals) for 10-15 min, 227
and then cells were injected into the chamber and allowed 10-15 min to adhere. Medium exchange from 228 SC (2% galactose) to SC (2% galactose) + glucose (4% final) was done by pipetting quickly, while the 229 chamber is fixed on the microscope stage. Pre-glucose sample was considered as time 0 and glucose 230 repression time points were taken immediately after exchange of the medium. 231
For Mig1p-GFP nuclear localization kinetics, microscopy was performed with an inverted 232 epifluorescence microscope (Ti-E, Nikon, Tokyo, Japan) using a 100x objective (Plan Fluo, NA 1.40, oil 233 immersion) and standard filter sets. Images were acquired using a cooled EMCCD camera (iXon3 897, 234
Andor, Belfast, United Kingdom). For delayed Mig1p response (longer time points), microscopy was 235 performed with a Nikon Ti-E microscope equipped with a CFI Plan Apo lambda DM 100x objective and a 236
Prior Scientific Lumen 200 Illumination system. All images were acquired using NIS Element software 237 and data analysis was done using Quantity One (Bio-Rad). Ratio of nuclear/cytoplasmic GFP intensity 238 was calculated as [(nuclear GFP intensity -background) / (cytoplasmic GFP intensity -background)]. 239
Obtained values for glucose repression time points were normalized to pre-glucose (time 0, t0) value. 240
Non-responding cells were quantified similarly, except for the fact that there was no visible nuclear foci, 241 thus a random, central area was selected and measured for fluorescence intensity. Position and area of 242 the measurement was kept identical for all the time points for the same cell. We reasoned that a non-243 responding cell would not have a distinct change over time in nuclear/cytoplasmic GFP intensity, hence 244 quantifying a random area as nucleus should not have an overall affect on the interpretation of the data. 245 246
RESULTS 247
Pol II catalytic mutants decrease steady state Pol II occupancy and apparent processivity. 248
To explore in vivo consequences of altered Pol II activity, we examined a subset of Pol II active site 249 mutants in the largest subunit Rpb1. These mutants were previously characterized biochemically, 250 molecularly, and genetically as falling into two classes (4, 5, 8, 9) . These two classes of Pol II mutants 251 appear to derive from either increase ("GOF") or decrease ("LOF") in Pol II catalytic activity, as 252 determined using in vitro transcription. First, we examined Pol II occupancy by chromatin IP over an 253 inducible long reporter gene, GAL1p::YLR454w (Figure 1A and (29)). We observed decreased overall 254 polymerase occupancy for both GOF and LOF mutants compared to WT (Figure 1B) . Among the 255 mutants tested, H1085Y (strong LOF) and G1097D (strong GOF) showed the most severe defects in Pol 256 II occupancy, consistent with their severe growth defects in vivo (4). When we normalized the Pol II fold-257 enrichment over the 5' end of the gene body ("1kb" amplicon) followed by normalization of mutant values 258 to WT, catalytic mutants show selective decrease in occupancy over the 3' end of the reporter (most 259 obvious for G1097D) ( Figure 1C ). Decreased steady state Pol II occupancy at the 3' end is consistent 260 with a processivity defect, wherein Pol II that begins synthesis is unable to complete the transcript, 261 leading to polar effects on occupancy from 5' to 3'. Generally, greater Pol II occupancy over 5' ends of 262 transcription units relative to 3' ends are interpreted as processivity defects when observed (29); 263 however, a faster elongation rate over a gene's 3' end would lead to a similar phenotype. Because 264 differential elongation rates over different parts of genes has been observed in mammalian cells (51-53), 265
we are careful to assert that what we observe is differential apparent processivity for Pol II mutants as 266
ChIP is unable to distinguish between the two possibilities. 267
Additional factors may determine Pol II occupancy levels over genes. For example, Pol II occupancy 268 over a template may be gene class-dependent or regulon-specific, given that external perturbations such 269 as changes in temperature or carbon source have been shown to affect transcription (54,55). Therefore, 270
we examined Pol II occupancy over the same reporter driven by a constitutive promoter 271 (TEF1p::YLR454w) with strains grown in glucose or galactose for the most severely defective Pol II LOF 272
and GOF mutants (Figure 1D and E) . We observed an increased Pol II occupancy for H1085Y in 273 galactose relative to glucose, with the converse for G1097D, compared to WT (Figure 1E) , although a 3′ 274 occupancy defect was still apparent for both mutants. WT Pol II showed more subtle changes in 275 occupancy in glucose relative to galactose. Furthermore, the G1097D 3′ end was enhanced in glucose 276 relative to galactose, suggesting growth conditional effects on transcription elongation. 277
Pol II catalytic mutants show decreases in reporter gene expression that are exacerbated by 278
promoter strength and template length. 279
Defective initiation or elongation might lead to decreased Pol II occupancy (56). Pol II activity mutants do 280 perturb initiation as most or all show defects in TSS selection (7, 8) . Mutants affecting Pol II elongation 281
have also been shown to affect reporter gene expression depending on length of the transcription unit 282 driven by identical promoters, using the so-called "GLAM" assay (32, 57) . Therefore, we determined if Pol 283 II catalytic mutants show gene expression defects based on gene length and/or promoter strength. We 284 measured Pol II catalytic mutants' effects on expression of YLR454w reporters in two different promoter 285 contexts, driven by the strong, inducible GAL1 promoter and the constitutive TEF1 promoter by Northern 286 blotting (Figure 2A) . Additionally, we also measured expressions of the endogenous GAL1 and TEF1 287 genes for comparison with YLR454w driven by the same promoters. Pol II mutants confer the strongest 288 effects on GAL1p::YLR454w expression compared to WT, with H1085Y and G1097D having the most 289 severe effects (Figure 2A) . Furthermore, we observed greater gene expression defects when examining 290 the highly expressed GAL1p::YLR454w relative to the more lowly expressed TEF1p::YLR454w. We also 291 found that expression defects for the YLR454w reporters were greater than defects observed for the 292 native genes (shorter in length) under control of their respective promoters (Figure 2A and 2B) . These 293 results are consistent with previous observations showing Pol II occupancy-and gene-length-dependent 294 effects on reporter expression for several elongation mutants (32, 56, 57) . Given reduced Pol II 295 occupancy and gene expression, it is likely that initiation defects might also be in play. When we 296 examined the kinetics of activation for GAL1p::YLR454w or GAL1, we found that activation of expression 297 was greatly delayed in Pol II mutant strains, consistent with defects in activation or initiation (Figure 2C) . 298
Pol II catalytic mutants show allele-specific genetic interactions with pre-mRNA processing 299 factors. 300
We observed greater expression defects for the Pol II mutants compared to occupancy defects over the 301 same reporter GAL1p::YLR454w (compare Figure 1B with Figure 2A) . These results suggested that 302 there could be additional defects beside Pol II initiation or elongation defects contributing to decreased 303 abundance of the reporter mRNA in the mutants. As the abundance of cellular mRNAs is determined by 304 synthesis and degradation rates, we reasoned that overall expression defects observed for Pol II 305 mutants might stem from changes to mRNA stability and/or RNA processing. To start, we determined if 306
Pol II catalytic mutants show GAL1p::YLR454w processing defects. We took a two-pronged approach to 307 address processing defects. First, we examined genetic interactions between Pol II mutants and pre-308 mRNA processing/degradation factors; second, we asked if blocking pre-mRNA degradation pathways 309 could rescue gene expression defects of Pol II mutants. 310
We reasoned that an mRNA capping defect or premature termination could lead to degradation of pre-311 mRNA by nuclear 5′ or 3′-exonucleases, respectively, resulting in decreased abundance of 312
GAL1p::YLR454w. Thus, we tested if Pol II mutants showed genetic interactions with known nuclear 313 exonucleases that function in surveillance. Deletion of Rrp6, a component of the 3′-exonuclease 314 exosome complex, showed a slight negative genetic interaction with Pol II GOF mutants ( Figure 3A) . 315 Inactivation of Rat1 and Xrn1, two 5′-exonucleases, showed strong genetic interactions with GOF 316 mutants ( Figure 3A) . Rat1 is essential and functions in termination of Pol II at protein-coding genes 317 (58, 59) . Pol II LOF mutants partially suppressed the Ts phenotype of rat1-1, a conditionally viable allele 318 of RAT1. In contrast, Pol II GOF alleles showed synthetic sick interactions with rat1-1, consistent with 319 prior findings and model proposed for kinetic competition between termination and elongation (19, 20, 60) . 320
Rat1 works with an activating partner Rai1, which processes partially capped mRNA allowing Rat1 321 access (61). Growth defects of rai1∆ were slightly suppressed by both LOF and GOF mutants at 37˚C, 322
while dxo1∆, a recently described nuclear 5′-exonuclase (62), showed no strong genetic interactions with 323
Pol II alleles ( Figure 3A) . 324
We then asked if the mRNA processing mutants that showed genetic interactions with Pol II mutants 325
were able to modulate Pol II alleles' gene expression defects. As predicted from the lack of strong 326 genetic interactions, deletion of Rrp6 did not rescue full-length GAL1p::YLR454w expression level 327 significantly; furthermore the nuclear exosome would be expected to mainly degrade prematurely-328 terminated transcripts and not-full length ones (Supplementary Figure 1A) . Deletion of XRN1 slightly 329 rescued GAL1p::YLR454w expression level in Pol II GOF mutant E1103G (Supplementary Figure 1A) . 330 Inactivation of Rat1 (at the restrictive temperature, 37˚C) severely decreased GAL1p::YLR454w 331 expression levels in both WT and catalytic mutants possibly due the rat1-1 growth defect, although 332 relative levels of GAL1p::YLR454w in WT and Pol II mutants didn't differ greatly between permissive 333 (27˚C) and restrictive temperature (37˚C) (Supplementary Figure 1B) . We found that xrn1∆/rat1-1 334 double mutant strains were extremely sick on YPGal even at permissive temperature (Supplementary 335 Figure 1C ). Hence, for determination of GAL1p::YLR454w expression level we used YPRaf/Gal liquid 336 medium, which allows growth of Pol II mutants in the xrn1∆/rat1-1 background. Intriguingly, inactivation 337 of both Xrn1 and Rat1 together completely rescued the GAL1p::YLR454w expression level in E1103G 338 (xrn1∆/rat1-1) compared to WT (xrn1∆/rat1-1) at 37˚C (Figure 3B ), suggesting possible 5′ end 339
processing-defective or 5′-cap defective transcripts in the GOF mutant E1103G are stabilized by 340 inactivation of Xrn1 and Rat1. Taken together these genetic interaction results suggest Pol II GOF 341 mutants may have 5' end processing or capping defects, rendering transcripts sensitive to Rat1/Xrn1. 342
Both slow and fast Pol II catalytic mutants confer increased mRNA stability to a reporter gene. 343
We reasoned that in addition to myriad Pol II transcription defects and pre-mRNA processing defects 344 discussed above, compromised mRNA stability of the GAL1p::YLR454w transcript may also contribute 345
to its lower abundance in Pol II catalytic mutants. In order to determine if Pol II mutants alter mRNA 346 stability, we performed transcriptional shutoff followed by measurement of GAL1p::YLR454w mRNA over 347 a time course by Northern blotting. mRNA half-lives were determined by fitting decay curves with a lag 348 followed by exponential decay (Supplementary Figure 2A) . We found that all GOF and LOF mutants 349 conferred an increase in both the YLR454w half-life and lag periods prior to exponential decay relative to 350
WT (Figure 4A, Supplementary Figure 2B-H) . Further, the increases in mRNA half-lives positively 351 correlated with the overall decrease in expression level of the reporter in the mutants (Figure 4B,  352 Supplementary Figure 2I) . These results suggest a number of conclusions. First, they indicate defects 353 in mRNA synthesis rates for all tested Pol II mutants, as steady state expression levels were reduced 354 relative to wild type even though we found that the GAL1-YLR454w mRNA showed increased stability. 355
Second, longer lag periods prior to exponential decay may indicate Pol II mutants confer a delayed 356 response for transcriptional shutoff, slower elongation rate on this template, or delayed mRNA export 357 (addressed below). Such lags have been observed in genome-wide experiments for mRNA stability 358
where transcription inhibitor blocks initiation but elongation is allowed to proceed (63). The lag can result 359 from the time it takes polymerases that have initiated prior to the block to finish synthesis of their 360 messages. Given that mRNA decay is strongly coupled to translation, and translational demand is 361 coupled to growth rate, it may be difficult to deconvolute Pol II mutant effects on mRNA decay through 362 changes to growth rates versus direct effects on mRNA decay. Indeed, we observed that mRNA half-363 lives positively correlated with strain doubling times (Figure 4C, Supplementary Figure 2J) . 364
Slow and fast Pol II catalytic mutants exhibit slower apparent in vivo elongation in a commonly 365 used ChIP assay 366
Our observation of longer mRNA decay lag times than WT for all Pol II mutants tested, both slow and 367 fast, was unexpected under the presumption that Pol II mutants that are fast elongaters in vitro are also 368 fast in vivo. In our mRNA decay experiments, longer lag times prior to exponential decay for LOF 369 mutants were consistent with delayed clearance of the template and predicted slow elongation kinetics. 370
Conversely, GOF mutants would be predicted to run off the template more quickly. In contrast to this 371 prediction, GOF mutants also showed longer lag times prior to exponential decay (Figure 4A) . One GOF 372 mutant tested here, E1103G, was previously suggested to be faster than WT in vivo based on chromatin 373 IP analysis of the same GAL1p::YLR454w reporter used here (19) . Therefore, we examined elongation 374 of E1103G and additional Pol II alleles in vivo using this commonly used ChIP assay. In this assay, 375 transcription of GAL1p::YLR454w is shutoff by addition of glucose to the medium, and the kinetics of the 376 last wave of Pol II transcription clearing the gene is measured using ChIP (Figure 5A and 5B) (29) . As 377 predicted, LOF mutants N479S and H1085Y showed extensive delay in Pol II run-off kinetics following 378 the transcriptional shut-off (Figure 5C and D) . The apparent in vivo elongation rate of H1085Y was 379 slower than N479S, which is consistent with its stronger growth defects and in vivo phenotypes relative 380 to N479S. Surprisingly, both test GOF mutants, E1103G and G1097D, also showed reduced kinetics of 381
Pol II runoff subsequent to glucose addition (Figure 5E ). This result was unexpected, especially as 382 E1103G was reported to have a faster apparent elongation rate than WT in a version of this assay (19) . 383 Furthermore, analogous substitution in human POLR2A E1126G confers a slightly faster than WT 384 elongation rate in vivo (15). 385
Given the discrepancy between our results and those of Hazelbaker et al (19) , we felt it was essential to 386 closely examine Pol II mutant behavior in the elongation assay and identify if there is any hidden or 387 confounding variable. We first extensively validated our GOF mutant strains in three ways -i. 388 confirmation of introduced mutations by sequencing, ii. confirmation of transcriptional growth phenotypes 389 as described in (4), and iii. confirmation of mutants' ability to shift transcriptional start sites (TSSs) at the 390 ADH1 promoter as described in (4,7,8) (Supplementary Figure 3A) . In all cases, results were 391 consistent with strains showing expected phenotypes, leading us to speculate that there might be 392 confounding variable(s) in the ChIP elongation assay itself. While we employed the most commonly 393 used method to shutoff GAL transcription by direct addition of glucose to the media (29), in Hazelbaker 394 et al (19), cells were washed in the absence of any carbon source prior to addition of glucose. We 395 repeated the method of (19) with the addition of a critical control, taking a time point just post wash (W0) 396
to determine how the wash step affected Pol II occupancy. In our hands, GOF E1103G was still slower 397 exiting the template than WT (Figure 5F) , consistent with both our direct glucose shutoff without 398 washing, and our measurement of increased lag in mRNA decay experiments (Figure 5E and 4A) . 399 Additionally, we observed two more phenomena during the wash. First, the W0 time point showed 400 evidence of transcriptional shutoff for both WT and E1103G, presumably due to galactose depletion (see 401 below for further discussion). We confirmed that Pol II run off was not due to delayed formaldehyde 402 cross-linking, as we did not detect any difference in Pol II occupancy when crosslinking was 403 simultaneous with the addition of glucose (Supplementary Figure 3B) . Second, GOF E1103G showed 404 a faster loss of Pol II over the 3' end of GAL1p::YLR454w early in the time course (W0) that was not 405 observed in the direct glucose shutoff assay (compare Figure 5E with 5F) . Together, these results 406
indicate that the mode of transcription inhibition could alter Pol II transcriptional properties in unexpected 407 ways, additionally confounding ability to estimate apparent Pol II elongation rate. 408
The absence of galactose itself is a distinct mechanism of transcription shutoff for GAL genes. Depletion 409 of galactose will lead to reestablishment of Gal80-mediated repression of Gal4, the critical activator of 410 GAL transcription. To examine this mode of transcription shutoff further, without the mixing of two distinct 411 modes of repression, we performed a galactose starvation/depletion time course where no sugar was 412 added. We found similar 3' specific runoff in E1103G early in the time course (W0) when a wash was 413 employed (Figure 5G) . As Pol II runs into the gene 3' end at later time points (presumably), the effect 414 diminishes. Additionally, in this iteration of the experiment there appears to be faster loss of E1103G 415 than WT from the 5' end of the reporter early, though E1103G is maintained much longer over the 3' end 416 later in the time course (Figure 5G) . Taken together, we find that Pol II GOF mutants, where tested, 417
appear to be retained longer on the template, when examined in the GAL1p::YLR454w system. We 418 observe this under three distinct transcription shutoff conditions and in all cases our results contradict 419 previously published results for Pol II GOF E1103G. However, our studies suggest that E1103G effects 420 on the 3' end of GAL1p::YLR454w upon galactose starvation (during wash) and unintended variability in 421 wash time between strains could account for the observed differences in our experiments and previous 422 observations. 423
Finally, we examined alternative in vivo evidence for putative fast and slow elongation of Pol II GOF and 424 LOF mutants. We analyzed how Pol II mutants altered termination at SNR33. It has been proposed 425 previously that kinetic competition between elongating Pol II and Sen1 helicase determines the 426 termination of the snR33 transcript (19). Examination of snR33 intermediate transcripts prior to complete 427 processing allows detection of the snR33 termination window (Figure 6A) . Both GOF mutants E1103G 428 and G1097D increase the average length of pre-processed snR33, which is in agreement with previous 429 observations for E1103G (Figure 6B and (19) ). Conversely, LOF mutants N479S and H1085Y 430 decreased the average length of pre-processed snR33 (Figure 6B) . We also observed alternative 431 mature snR33 transcripts longer or shorter in length for GOF and LOF mutants, respectively, consistent 432
with increased upstream or downstream utilization of transcription start site (TSS) in these mutants as 433 predicted for alterations in catalytic rate. 434
Glucose signal transduction defects in Pol II alleles may partly explain apparent slow elongation 435
by ChIP 436 One contribution to apparent slower elongation of GOF mutants on the GAL1p::YLR454w template could 437 be delayed transcriptional shutoff. We reasoned that if glucose repression (or galactose starvation) were 438 delayed in GOF mutants, it would add to apparent slow kinetics of Pol II exiting the gene. To this end, we 439 investigated the kinetics of nuclear localization of Mig1p, which upon addition of glucose to medium is 440 imported into the nucleus due to regulation by dephosphorylation, binds to target promoters of glucose-441
repressed genes and recruits co-repressors (64,65). As a proxy for early events in this cascade, we 442 determined the kinetics of Mig1p nuclear localization by monitoring import of Mig1p-GFP upon glucose 443 addition in WT or GOF catalytic mutants We observed signal for presumptive Mig1p-GFP localization to 444 the nucleus saturate within ~2 min for WT cells, as previously reported (66). However, for at least one 445 GOF mutant, the signal did not appear to reach maximum nuclear fluorescence within 2 min of glucose 446 addition, thus we measured extended time points and analyzed the data from individual cells using non-447 linear regression (Figure 7A and B) . GOF G1097D showed both a delay in average time of Mig1p-GFP 448 nuclear import and reduced average maximum nuclear fluorescence compared to WT, suggesting in 449 vivo shutoff kinetics may be delayed due to deranged Mig1p signaling in this mutant at least ( Figure  450 7B). Next, we measured extended time points of Mig1p translocation upon glucose repression over 451 populations of individual cells for the GOF mutants analyzed in Figure 7A/B , while also including one 452 LOF mutant, N479S. A noticeable subset of delayed responding cells was observed for GOF mutant 453 G1097D, while higher fractions of non-responding cells were observed for both GOF mutants and the 454 LOF mutant N479S compared to WT (Figure 7C and Supplementary Figure 4) . Both GOF mutant 455 G1097D and LOF mutant N479S showed lower average maximum nuclear Mig1p-GFP accumulation 456 compared to WT, with the LOF mutant N479S showing an increase, then decrease, in Mig1p-GFP signal 457 over time (Supplementary Figure 4) . Altogether, these results indicate that Mig1p nuclear translocation 458
in Pol II catalytic mutants can be aberrant, potentially affecting interpretation of transcription kinetics 459 upon glucose shutoff. However, the strengths of observed apparent signaling defects do not appear to 460 explain the large apparent fractions of retained mutant Pol II molecules at the 3′ end of 461
GAL1p::YLR454w. 462
Pol II catalytic mutants do not confer sensitization of cells to GTP starvation through 463 hypothesized global elongation defects 464
To understand the relationship between altered Pol II activity and growth defects derived from putative 465 global elongation defects, we turned to pharmacological reduction of a Pol II substrate, GTP. Nucleotide 466 depleting drugs such as MPA or 6-AU have been interpreted as specifically exacerbating global 467 elongation defects of Pol II or transcription factor mutants, and therefore have been widely used as 468 pharmacological probes for transcription elongation in vivo. MPA depletes GTP through inhibition of the 469 inosine monophosphate dehydrogenase (IMPDH) activities encoded by two MPA-sensitive IMPDH 470 paralogs, IMD3 and IMD4. WT cells are resistant to MPA because they are able to induce an MPA-471 resistant IMPDH-encoding paralog IMD2 upon MPA-induced GTP starvation (Figure 8A) . Interpretations 472 of MPA sensitivity assume that WT and mutant strains have similar GTP starvation upon MPA treatment. 473 We and others have noted that WT and MPA-sensitive mutants can experience different levels of GTP 474 starvation due to different expression levels of the IMD2 gene product, which provides MPA-resistant 475 IMPDH activity as noted above (67-69). These differences in IMD2 expression explain why increased 476 catalytic activity Pol II GOF mutants are MPA sensitive -they do not express IMD2. In contrast, Pol II 477 LOF mutants constitutively express IMD2, and do not show MPA sensitivity. We chose to evaluate how 478
Pol II responds to GTP starvation and determine if Pol II transcription is a critical determinant for cellular 479 sensitivity to GTP starvation. To do so, we rendered GTP starvation independent of IMD2 expression by 480 deleting IMD2. Deleting IMD2 is predicted to normalize GTP starvation between WT and Pol II mutants, 481 allowing us to examine the assertion that GTP depletion exacerbates putative Pol II elongation defects in 482 vivo (Figure 8A) . Furthermore, to enable an in vivo readout for IMD2 expression, we replaced the IMD2 483 ORF with HIS3 (Figure 8A, lower panel) . 484
In the absence of IMD2, otherwise wild type yeast strains become sensitive to MPA treatment as 485 expected (Figure 8B) (67,68) . If Pol II transcription were a major determinant of GTP starvation, it would 486 be predicted that elongation-defective LOF Pol II alleles would become hypersensitive to MPA, while 487 GOF increased catalytic activity mutants would show relative resistance. In contrast to these predictions, 488
deletion of IMD2 strongly blunted the Pol II allele-specific effects of MPA treatment on yeast cells 489 (Figure 8B) . We did observe mild MPA sensitivity for Pol II GOF alleles E1103G and G1097D. These 490 results suggest that the major determinant for Pol II allele sensitivity to MPA is differential IMD2 491 expression, and not necessarily Pol II elongation defects. As stated earlier, MPA effects are presumed to 492 function through GTP starvation. This presumption can be tested by addition of guanine to the growth 493 medium, which can suppress MPA-sensitivity by supporting an alternate route for GTP synthesis. In 494 testing this presumption, we found that use of 10 mM NaOH to solubilize guanine in the medium on its 495 own reduced effects of MPA on most of the Pol II mutants (Supplemental Figure 5) . Notably, some of 496 these Pol II mutants have shown allele-specific phenotypes upon change to pH of media (13). We 497 determined that addition of equivalent HCl to neutralize NaOH effects allowed examination of guanine 498 suppression of MPA sensitivity (Figure 8B) . We observed that addition of guanine suppresses MPA 499 sensitivity for most Pol II mutants except the GOF mutants E1103G and G1097D, which show mild or no 500 suppression of MPA sensitivity by guanine, respectively. These results suggest that either the IMD2-501 independent MPA effects on GOF mutants are independent of GTP starvation, or these mutants have 502 alterations in their GTP salvage synthesis pathways. We next determined if the ability to induce the 503 IMD2 promoter was maintained in Pol II mutants when GTP starvation conditions were normalized, using 504 growth on medium lacking histidine to detect expression of imd2∆::HIS3 (Figure 8C) . WT cells and GOF 505 mutants were almost completely His in the absence of induction of the IMD2 promoter (controlling 506 HIS3), while LOF mutants were His + , indicative of constitutive expression of imd2∆::HIS3. All strains 507 showed induction of His + phenotype in the presence of MPA (inducer of IMD2 promoter), suggesting that 508 productive transcription from the IMD2 promoter was possible for all tested Pol II mutants (discussed 509 further below). 510
A number of transcription factor mutants have been described as either MPA or 6-AU sensitive with 511 these sensitivities interpreted as indicative of Pol II elongation defects. Such mutants include deletions in 512 known elongation factor genes dst1∆ (encodes TFIIS, (42,70)), spt4∆ (subunit of Spt4/Spt5 DSIF, (71-513 73)), paf1∆ (Paf1C complex member, (38,74) ), bur2∆ (P-TEFb subunit homolog, (72)), pop2∆ (encodes 514
Ccr4/NOT complex member, (42,75)) or deletions in genes encoding subunits of transcriptional 515 coactivator complexes spt3∆, sgf73∆ (SAGA, (38, 42) ) or gal11∆ (Mediator, (42) ). It has previously been 516 demonstrated for some of these mutants, including dst1∆, spt3∆ and paf1∆, that IMD2 induction is 517 defective (38,42), indicating differential GTP starvation upon drug treatment for these strains relative to 518 WT, just as for the Pol II mutants described above. We characterized these strains' sensitivity to MPA 519 treatment in presence or in the absence of endogenous IMD2 (Figure 9) . We observed that some of the 520 mutants including sgf73∆ and pop2∆ were only slightly sensitive to MPA in presence of IMD2 ( Figure  521 9A, top panels). However, in the absence of IMD2, only spt3∆ showed MPA hypersensitivity relative to 522 WT, with dst1∆ showing only slight sensitivity relative to WT. We next examined suppression of 523 observed MPA sensitivities by guanine supplementation (Figure 9A, bottom panels) . We observed that 524 spt3∆ was entirely suppressed by guanine, dst1∆ mostly suppressed, and spt4∆, paf1∆, and gal11∆ 525 much less so. We hypothesize that spt3∆ hypersensitivity relates to defects in TPO1 expression, which 526 is known to modulate MPA sensitivity (38). Taken together, these results are inconsistent with putative 527 global Pol II transcription defects being a critical determinant for cell growth under GTP limitation. We 528 further examined if IMD2 promoter function in response to MPA were intact in the cohort of transcription 529 factor mutants tested (Figure 9B) . We observed a His + phenotype consistent with constitutive 530 expression of imd2∆::HIS3 in spt4∆. This phenotype suggests possible altered initiation in spt4 mutants 531 as observed in LOF Pol II mutants (Figure 8C) . Furthermore, we observed that the His + phenotype was 532 inducible in the presence of MPA for all factor mutants except spt3∆. These results indicate that 533 presumptive GTP sensing is maintained in most mutants, but that spt3∆ cells have a distinct defect not 534 observed for other factor mutants or Pol II mutants. This defect indicates an almost complete inability to 535 induce the IMD2 promoter::HIS3 reporter, although spt3∆ is known to express IMD2 upon MPA 536 treatment at a very low level in presence of endogenous IMD2 (42). 537
Pol II catalytic mutants do not abolish the response to GTP depletion but derange TSS usage at 538 IMD2 promoter. 539
By removing the possibility of differential IMD2 expression complicating the MPA response (using 540 imd2∆), we showed above that many factor mutants or Pol II catalytic mutants have similar responses to 541 MPA treatment. These results indicated Pol II transcription is not especially sensitive to presumptive 542 GTP starvation in vivo relative to other pathways that rely on GTP (Figure 8 and 9) . To better 543
understand the mechanism of IMD2 expression defects in the absence of differential GTP starvation, we 544 further analyzed transcriptional responses at the IMD2 promoter upon MPA treatment. Using the same 545 imd2∆::HIS3 reporter construct used above, we analyzed the kinetics of TSS utilization upon addition of 546 a concentration of MPA that induces a TSS shift at the IMD2 promoter (Figure 10A) . Pol II has been 547 proposed to directly sense GTP levels through its active site, and through this sensing Pol II catalytic 548 activity controls IMD2 TSS usage (41). Under this model, it would be predicted that LOF Pol II mutants 549 might show precocious downstream TSS usage; indeed, this behavior has previously been observed (4). 550
Conversely, under this model, catalytically GOF Pol II mutants would show delayed TSS shifting kinetics 551 due to their relative insensitivity to reduced GTP levels. 552
We observed that both LOF (H1085Y) and GOF (E1103G) mutants gradually lose upstream 'G' sites 553 upon MPA treatment (Figure 10B) , indicating retention of ability to respond to GTP-depletion. As 554 expected, WT cells rapidly lose upstream 'G' TSSs and subsequently gain the downstream functional 'A' 555 TSS (Figure 10C) . H1085Y constitutively uses the downstream functional 'A' TSS and shows increased 556 usage of this site upon MPA treatment, while showing decreased kinetics of loss of upstream TSSs. This 557 result is unexpected from the "defective GTP sensing" model where kinetics of upstream TSS loss are 558 predicted to be faster than WT, not slower for Pol II LOF mutants (Fig 10 B and C) . E1103G shows 559
reduced kinetics of loss of upstream site, consistent with defective GTP sensing, but shifts TSS usage to 560
novel TSSs predicted to be nonfunctional due to their position upstream of the IMD2 Nab3/Nrd1-561 dependent terminator (Figure 10B and C) . have previously been observed in sen1, nab3 and rpb11 mutants (41). Indeed, deletion of the exosome 566 subunit Rrp6 also stabilized CUTs derived from the novel TSSs we observe, with significant utilization of 567 these TSSs in E1103G compared to WT (Figure 10D and Supplementary Figure 6A-B) . Stabilization 568 of these CUTs in rrp6∆ strains did not provide MPA resistance for MPA sensitive Pol II GOF mutants, as 569 these transcripts do not likely produce functional IMD2 transcript required for resistance even if stabilized 570 (Supplementary Figure 6C) . We note that although E1103G generally appears unable to utilize 571 downstream functional 'A' TSS upon MPA treatment, enough functional transcript was made to produce 572 a His + phenotype in the presence of imd2∆::HIS3 at low concentrations of MPA treatment (Figure 9B) . 573
Our results here provide an initiation-based mechanism for the MPA sensitivity of Pol II GOF mutants. 574 575 Discussion 576
Examination of Pol II catalytic mutants by our lab and others has shown Pol II activity-sensitive aspects 577 of transcription initiation, elongation, co-transcriptional processes, and termination (4, 7, 8, 15, 19, 20) . Our 578 current study utilizes a set of yeast Pol II catalytic mutants to probe broad aspects of gene expression in 579
vivo. We show that Pol II catalytic defects lead to a decrease in overall Pol II occupancy with reduction in 580 3' end occupancy on a galactose inducible reporter gene, GAL1p::YLR454w (Figure 1) . Further, using a 581 constitutively expressed TEF1p::YLR454w reporter we find that growth on different carbon sources may 582
alter Pol II occupancy profiles (Figure 1) . Previously, several observations suggested alterations of Pol II 583 activity and gene expression due to external perturbations such as carbon source or temperature 584 (54, 55) . Likewise, environmental stress has also been shown to affect Pol II activity and gene expression 585 (78). Notably, it has also been shown that RAS/PKA signaling pathway, which controls aspects of 586 glucose signaling, can target proteins associated with general transcription machinery, can putatively 587 regulate elongating Pol II by targeting Spt5/4 (79, 80) , and shows interactions with Nab3/Nrd1 termination 588 factors (81). In addition to differential effects of carbon source on steady state Pol II occupancy, we also 589 observe impaired galactose induction and glucose repression kinetics in both LOF and GOF mutants 590 (Figure 2 and 7) . Interestingly, both classes of catalytic mutants show impaired growth at 37˚C on 591 galactose likely arising from the sum of a number of distinct individual defects in initiation, elongation, 592
and termination (Supplementary Figure 1B) . Taken together, these results support growth condition-593 dependent modulation Pol II elongation in vivo. 594 595
Pol II mutant rpb1 E1103G, which was reported previously to be fast for elongation in vivo relative to WT 596 (19), appears slower than WT in our study. In vitro biochemical studies, including direct observations of 597 individual polymerases at the single molecule level, have repeatedly shown faster elongation rate for 598 E1103G compared to WT (4, 6, 12, 14) . Several lines of evidence suggest E1103G in vitro GOF activity 599 manifests itself in vivo through transcriptional effects distinct from LOF mutants. First, primer extension 600 analysis shows that E1103G shifts TSS usage upstream at a number of promoters, consistent with a 601 model that increase in catalytic activity increases initiation probability during Pol II promoter scanning, 602 resulting in observed upstream TSS shifts (4,7). Second, E1103G and other Pol II GOF mutants show 603 allele-specific genetic interactions with a number of factors, suggesting their defects are distinct from 604 LOF mutants (7). For example, the synthetic sick genetic interaction of E1103G with the RNA processing 605 factor alleles rat1-1 and xrn1∆/rat1-1 is consistent with exacerbation of termination defects through faster 606 elongation (18) (19) (20) 60) , and in contrast to the suppression of rat1-1 and rat1-1/xrn1∆ by LOF Pol II alleles. 607
Indeed, delayed termination for GOF E1103G was evident through observation of increased length of 608 pre-processed snR33 (Figure 6) . We further show that an even stronger GOF mutant, G1097D, shows a 609 corresponding increase in pre-processed snR33 length relative to E1103G or WT. While increased 610 length of pre-processed snR33 is consistent with increased elongation rate in GOF mutants, defective 611 termination due to altered probability of a Pol II conformational change should not be ruled out as 612 possible mechanism (21). Finally, a recent study demonstrated that an E1103G strain displays a shift in 613 co-transcriptional splicing towards downstream positions, consistent Pol II traveling further downstream 614 prior to splicing, though delayed splicing kinetics cannot be ruled out (16). Altogether, these data are 615 consistent with increased elongation kinetics in GOF catalytic mutants in vivo under a parsimonious 616 view, though they do not explain the delayed Pol II runoff from YLR454w observed here. We speculate 617 that template, context (such as distance from promoter, position within gene, or gene expression level), 618
or condition-specific effects may contribute to either slow elongation or template retention in fast Pol II 619 catalytic mutants in some genomic locations. 620 621
Our results suggest that the commonly used glucose shutoff assay for determining in vivo elongation 622 rate may be confounded by previously unappreciated limitations and biological complexity. We also 623 identify a possible artifact of prior experimental design that may have contributed to discrepant results 624 reported for GOF mutant E1103G. First, we have shown that galactose starvation induces as fast a 625 transcriptional shutoff at GAL1p::YLR454w as glucose addition (Figure 5F) . Second, this galactose-626 depleted transcriptional shutoff affects Pol II E1103G differently than WT. During the wash, E1103G Pol 627 II runs off both the 5' and 3' ends of the reporter faster than WT (Figure 5F-G) . 5' runoff is consistent 628 with E1103G elongating faster than WT early in the time course, or E1103G being more sensitive to 629 galactose starvation. The increased runoff kinetics from the 3' end of the reporter in E1103G is 630
perplexing. Furthermore, after these early effects observed for E1103G relative to WT under galactose 631
starvation, E1103G Pol II shows a delay in running off the template at longer time points regardless of 632 mechanism of shutoff, just as purported LOF Pol II alleles do under glucose inhibition. From these 633 results we can only conclude that Pol II could be differentially affected while on the 3' end of the gene 634 relative to the middle under different growth conditions. Further, we identified slow Mig1p nuclear 635 translocation upon glucose exposure as a possible confounding variable for use of GAL1p::YLR454w to 636 determine in vivo elongation rate. There may be additional untested steps in inhibition specific to the 637 GAL system that are defective, or defects specific to the long YLR454w template for Pol II GOF strains. 638
Regardless, careful consideration of possible variables in assay behavior is urged given the results we 639 present. 640 641
In order to exploit the existing transcription reporter systems to probe transcription mechanisms 642 carefully, we need a detailed understanding of each phenotypic system, such as our analyses to dissect 643
the Spt phenotype of Pol II GOF alleles (82). Here we investigated Pol II catalytic mutants and several 644 transcription factors mutants' response to the nucleotide-depleting drug MPA under conditions where 645 differential IMD2 expression was obviated. Most tested Pol II mutants and many transcription factor 646 mutants behave similarly to WT upon MPA treatment of imd2∆ strains (Figure 8 and 9) . Our results also 647 suggest IMD2-independent mechanisms of MPA sensitivity, which have been observed in previous 648 large-scale deletion screens for MPA or 6-AU sensitivity, and have identified Pol II mutants and 649 transcription factor mutants that do not affect IMD2 transcription (38, 42) . Our previous analyses 650 identified a correlation between MPA sensitivity of Pol II GOF alleles and upstream shifts in TSS usage 651 at ADH1 (4,7). As IMD2 regulation proceeds by initiation shifting from upstream non-productive TSSs to 652 a downstream productive one, it is conceivable that initiation defects underlie Pol II mutant MPA 653 sensitivity. However, in the presence of endogenous IMD2 it is difficult to determine mechanisms of MPA 654 sensitivity of GOF mutants, as they would be differentially starved for GTP due to differential expression 655 of functional IMD2 upon MPA treatment. One model for MPA sensitivity based on differential sensitivity 656 to reduced GTP is that increased catalysis rate of GOF alleles might buffer reduction in substrate (GTP) 657 levels. This could lead to delay in sensing low GTP and switching IMD2 upstream GTP-initiated TSSs to 658 downstream ATP-initiated TSSs, causing acute GTP starvation possibly beyond a critical threshold for 659 growth/viability. Our results disfavor this model. Here we present evidence that MPA sensitivity of the Pol 660 II GOF allele E1103G correlates with usage of novel TSSs that are intermediately positioned between 661 the known productive -106 A TSS at IMD2 and upstream non-functional starts. We conclude that IMD2 662 defects in Pol II GOF E1103G are likely to derive from initiation defects (Figure 10) . 663 664
Our Pol II catalytic mutants and pre-mRNA processing factor show allele-specific genetic interactions 665 (Figure 3) . Synthetic sick interactions of GOF with xrn1∆ and stabilization of the GAL1p::YLR454w 666 transcript in the xrn1∆/rat1-1 double mutant background is suggestive of a 5'-end processing defect in 667 GOF mutants, possibly a capping defect. A defect in capping would be predicted to expose mRNA to the 668 action of 5' exonucleases Xrn1 and Rat1. Capping of nascent transcripts occurs co-transcriptionally with 669
Pol II elongation proposed to be coupled to successful capping, though a direct "capping checkpoint" has 670 yet to be shown (83, 84) . Potential sensitivity of capping to Pol II GOF mutants is suggestive of either a 671 defective checkpoint in Pol II mutant strains or the absence of one. We also observe correlations of 672
reporter transcript half-life with expression levels in Pol II mutants, and with Pol II mutants' growth 673 defects (Figure 4) . Observed correlations between mRNA decay rate with both expression and growth 674 rate is consistent with recent findings (27)(http://biorxiv.org/content/early/2016/03/19/044735).
675
'Feedback' of gene expression control between the abundance of mRNA and mRNA decay rates is 676
proposed to occur in response to defects in transcription synthesis (24, 25) . Alternatively, as growth 677 efficiency is connected to overall translational demand, mRNA decay 'feedback' may occur upon 678 alteration of overall translation rate, as most mRNA decay happens co-translationally (85-87). Given that 679
Pol II mutants show reduced apparent initiation based on overall Pol II occupancy and reduced growth 680
rates, it is difficult to deconvolute primary and secondary global effects. Although we looked at both 681 phenomena using a single reporter transcript, mutants described here could be used further to probe 682 these proposed mechanisms in large scale. 683 684
Here we extensively characterize a set of Pol II catalysis mutants for in vivo consequences. We show 685 that altered Pol II catalysis affects Pol II occupancy, putative elongation, and reporter gene expression 686 and decay rate in vivo. Notably, we interrogate two widely used elongation reporter systems, raising 687 caveats about their use and interpretation. For use of nucleotide depleting drugs MPA or 6-AU, we 688 constructed and tested a useful novel reporter system (imd2∆::HIS3), which can be further utilized to 689 characterize or screen for new mutants that shift TSS usage downstream, leading to constitutively 690 expression of imd2∆::HIS3. Development of approaches allowing more direct determination of in vivo 691 elongation rate will bypass issues identified here. Recent advances in high-resolution microscopy have 692 enabled real-time observation of all transcription phases on endogenous genes using fluorescently 693 labeled proteins that bind to nascent transcript (88, 89) . This approach could be to address how any 694 number of variables might modulate elongation such as template sequence, RNA secondary structure 695 etc, and likely represents the next steps toward understanding transcription elongation and co-696 transcriptional processes in vivo. 697 698
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Green and blue color-coding is used to annotate GOF and LOF mutants, respectively. This color-coding 951 is used throughout. (C) Pol II catalytic mutants show apparent 3' processivity defects. Apparent Pol II 952 processivity defects determined for each mutant by normalizing mutant ChIP signal to signal at 1kb 953 followed by normalization to WT. (D) Schematic of constitutively expressed reporter gene 954 endogenous TEF1 levels from cells grown in galactose-or glucose-containing medium as indicated. 967
Values were normalized to WT TEF1p::YLR454w expression level in YPD. The most severe expression 968 defects are evident at GAL1p::YLR454w for both GOF and LOF mutants compared to WT. Individual 969 data points from at least three biological repeats are shown with error bars indicating average +/-970 standard deviation of the mean. (B) Endogenous GAL1 mRNA expression level is decreased in Pol II 971 catalytic mutant strains compared to WT, yet GAL1 expression defects in mutants are less severe than 972
GAL1p::YLR454w expression defects as showed in A. Values were normalized to WT GAL1 mRNA 973 level. Error bars as in A. (C) Pol II catalytic mutants delay induction of the GAL1 promoter. Time courses 974
showing induction of GAL1p::YLR454w and endogenous GAL1 mRNA in WT and Pol II catalytic 975 mutants. Overnight grown cells were inoculated into fresh YPRaf medium and grown until mid-log phase 976 at 30˚C, subsequently 4% galactose (final) was added to induce GAL gene expression. RNAs isolated 977 prior (time 0) and after galactose addition were used for Northern blotting to determine accumulation of 978 mature GAL1p::YLR454w and endogenous GAL1. Data normalized to WT 120 min value and plotted 979 using non-linear regression using GraphPad Prism. Individual data points from at least three biological 980 repeats are shown. 981 982
Figure 3. Allele-specific genetic interactions between Pol II catalytic mutants and pre-mRNA

